Figure 1From: Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy Kaplan-Meier-estimated PFS (dashed line) and OS curve (bold line) in LA-NSCLC patients treated with concurrent CRT (n = 159). Back to article page